课题基金 / 基金详情

Investigation for the development of vaccine against hepatitis C virus

Investigation for the development of vaccine against hepatitis C virus
丙型肝炎病毒疫苗的研制研究
批准号:
09670515
负责人:
MARUYAMA Toshiyuki
金额:
$1.98万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1998

项目摘要

项目成果

MARUYAMA Toshiyuki的其他基金

相似基金

相关文献

中文摘要
翻译
我们利用包含整个核心区域全长的重组HCV核心蛋白,从免疫原性、H-2连锁基因的影响、精细特异性以及与体内抗体产生的关系等方面研究了小鼠T细胞对HCV核心蛋白的反应。与HBcAg相比,HCV核心蛋白在体液和细胞反应方面的免疫原性明显较低。H-2连锁基因对HCV核心蛋白的体液应答的影响是可识别的,鉴定出高应答者(H-2f)、中应答者(H-2b, s)和低应答者(H-2k, d, p)单倍型。T细胞识别位点由小的(18个残基)合成肽确定。每个菌株识别一个主要的T细胞决定因素,这种识别过程的精细特异性取决于响应菌株的H-2单倍型。例如,H-2f菌株主要识别p41-55, H-2b菌株主要识别p11-25, H-2s菌株主要识别p161-175。当B10。用p41-55肽原免疫M (H2-f)小鼠,用HCV核心蛋白二次免疫后产生足够的免疫应答。因此,p41-55肽是抗HCV感染疫苗的良好候选肽。这些结果表明,HCV核心抗原的免疫应答受H-2连锁基因的影响,HCV核心抗原的免疫原性较低,具有临床意义,大多数急性HCV感染患者在早期产生较低的病毒蛋白抗体。
英文摘要
We have examined the murine T cell response to HCV core protein in terms of immunogenicity, the influence of H-2 linked genes, fine specificity, and relationship to in vivo antibody production by using recombinant HCV core protein which contains full length of entire core region. The HCV core protein was shown to have markedly lower immunogenicity compared to HBcAg on humoral and cellular response. The influence of H-2 linked genes on the humoral response to HCV core protein was discernible, and high responder (H-2f), intermediate responder (H-2b, s), and low responder (H-2k, d, p) haplotypes were identified. T cell recognition sites were defined by small (18 residue) synthetic peptides. Each strain recognized a predominant T cell determinant, and the fine specificity of this recognition process was dependent on the H-2 haplotype of the responding strain. For example, H-2f strain recognized p41-55, H-2b strain recognized p11-25, H-2s strain recognized p161-175 predominantly. When B10.M (H2-f) mice were primary immunized by p41-55 peptide, these mice had enough immune response after secondary immunization with HCV core protein. Therefore, p41-55 peptide is a good candidate for vaccine against HCV infection. These results that immune response to HCV core antigen is influenced by H-2 linked genes and that HCV core antigen is low immunogenic have clinical relevance most of patients with acute HCV infection produce lower antibodies against viral proteins in early phase.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
T.Maruyama: "Precore Wild type DNA and immune complexes persisl in chronic hepatitis B after seroconversion" Hepatology. 27. 245-253 (1998)
T.Maruyama:“Precore 野生型 DNA 和免疫复合物在血清转化后慢性乙型肝炎中持续存在”肝病学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
K.Koike,et al: "Sialadenitis resembling Sjogren's syndrome in hepatitis C virus envelope gene transgenic mice." Proc Natl Acad Sci USA. 94. 233-236 (1997)
K.Koike 等人:“丙型肝炎病毒包膜基因转基因小鼠中的唾液腺炎类似于干燥综合征。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Mitsui H,: "Thrombin activates two stress-activated protein kinases" Hepatology. 27. 1362-1367 (1998)
Mitsui H,:“凝血酶激活两种应激激活蛋白激酶”肝病学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
8
    Using microbubbles to increase the destruction of liver tumors by high-intensity focused ultrasound
    • 批准号:
      15390228
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.13万
    • 财政年份:
      2003
    • 负责人:
      MARUYAMA Toshiyuki
    • 依托单位:
    The comparison of virus genome and immune reaction between asymptomatic carriers and chronic hepatitis patients infected with HBV.
    • 批准号:
      13670495
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $0.64万
    • 财政年份:
      2001
    • 负责人:
      MARUYAMA Toshiyuki
    • 依托单位:
    The mechanism which causes fulminant hepatic failure after immune suppression therapy on HBV carrier patients
    • 批准号:
      11670480
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.92万
    • 财政年份:
      1999
    • 负责人:
      MARUYAMA Toshiyuki
    • 依托单位:
    国内基金
    海外基金
    CircSLTM及其编码多肽SLTM-99aa通过SAFB介导的mRNA剪接重塑在胃癌发生发展中的分子机制及其临床价值研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      胡柯峰
    • 依托单位:
    多囊卵巢综合征中甲酰肽受体2调控小胶质细胞代谢重编程导致GnRH神经元过度激活及HPO轴异常的病理机制研究
    • 批准号:
      82370797
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      陶弢
    • 依托单位:
    Peptide YY调控Hippo/YAP通路促进皮肤组织创面愈合的机制研究
    • 批准号:
      --
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2022
    • 负责人:
      王晓
    • 依托单位:
    靶向促黏多肽R-Peptide对iPSCs来源肝脏类器官培养体系的优化及机制研究
    • 批准号:
      32160230
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      36.00万元
    • 批准年份:
      2021
    • 负责人:
      姚佳
    • 依托单位: